HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jeffrey A. Hagen Tom R. DeMeester Otavio Gastal Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nigro, J. J. Articles by Bremner, C. G. Search for Related Content PubMed PubMed Citation Articles by Nigro, J. J. Articles by Bremner, C. G.

J Thorac Cardiovasc Surg 1999;117:960-968
© 1999 Mosby, Inc.

GENERAL THORACIC SURGERY

NODE STATUS IN TRANSMURAL ESOPHAGEAL ADENOCARCINOMA AND OUTCOME AFTER EN BLOC ESOPHAGECTOMY

From the University of Southern California, Departments of Surgery and Cardiothoracic Surgery, Los Angeles, Calif.

Read at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.

Received for publication July 15, 1998. Revisions requested Oct 1, 1998. Revisions received Jan 11, 1999. Accepted for publication Jan 12, 1999. Address for reprints: Steven R. DeMeester, MD, University of Southern California, Department of Cardiothoracic Surgery, Norris Comprehensive Cancer Center, 1441 Eastlake Ave, MS 74, Los Angeles, CA 90033.

Objective: Adenocarcinoma has replaced squamous cell as the most common esophageal cancer in the United States. The purpose of this study was to determine the prevalence and location of lymph node metastases, the feasibility of performing an R₀ resection, and disease recurrence and survival in patients with transmural adenocarcinoma of the lower esophagus and gastroesophageal junction.
Methods: Forty-four patients with transmural adenocarcinoma underwent en bloc esophagectomy with systematic thoracic and abdominal lymphadenectomy. They were followed up for a median of 23 months.
Results: Actuarial survival for the entire group was 26% at 5 years. The most important predictors of the likelihood of recurrent disease and 5-year survival were the presence and number of lymph node metastases and the ratio of involved to total removed nodes. Seven patients (16%) were found to have no lymph node metastases and had an 85% 5-year survival. In contrast, patients with more than 4 involved nodes or a node ratio greater than 0.1 had a high likelihood of recurrence and death. Location of involved lymph nodes did not predict the likelihood of recurrence or death. Despite all patients having transmural tumors, recurrence within the field of the en bloc resection occurred in only 1 patient (2%).
Conclusions: En bloc esophagectomy in patients with transmural esophageal adenocarcinoma is required to obtain the survival benefit of an R₀ resection, to adequately assess lymphatic tumor burden, and to be able to predict the likelihood of recurrence and death and thereby guide the use of postoperative adjuvant therapy.

This article has been cited by other articles:

				E. C. Paulson, J. Ra, K. Armstrong, C. Wirtalla, F. Spitz, and R. R. Kelz Underuse of Esophagectomy as Treatment for Resectable Esophageal Cancer Arch Surg, December 1, 2008; 143(12): 1198 - 1203. [Abstract] [Full Text] [PDF]

				G A WHITFIELD, A JACKSON, C MOORE, and P PRICE Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: what planning margins should we use? Br. J. Radiol., December 1, 2008; 81(972): 921 - 934. [Abstract] [Full Text] [PDF]

				A. C. Chang, H. Ji, N. J. Birkmeyer, M. B. Orringer, and J. D. Birkmeyer Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): 424 - 429. [Abstract] [Full Text] [PDF]

				D. R. Ferry, M. Anderson, K. Beddard, S. Tomlinson, P. Atherfold, J. Obszynska, R. Harrison, and J. Jankowski A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response Clin. Cancer Res., October 1, 2007; 13(19): 5869 - 5875. [Abstract] [Full Text] [PDF]

				C. Pedrazzani, G. de Manzoni, D. Marrelli, S. Giacopuzzi, G. Corso, A. M. Minicozzi, B. Rampone, and F. Roviello Lymph node involvement in advanced gastroesophageal junction adenocarcinoma J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 378 - 385. [Abstract] [Full Text] [PDF]

				C. Pedrazzani, G. de Manzoni, D. Marrelli, and F. Roviello It Is Time for a Proper Staging System for Adenocarcinoma of the Gastroesophageal Junction J. Clin. Oncol., March 1, 2007; 25(7): 907 - 908. [Full Text] [PDF]

				S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF]

				S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF]

				S. R. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30. [Abstract] [Full Text] [PDF]

				R. Iyer, N. Wilkinson, T. Demmy, and M. Javle Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy Ann. Surg. Oncol., July 1, 2004; 11(7): 665 - 673. [Abstract] [Full Text] [PDF]

				S. C. Malaisrie, B. Untch, G. V. Aranha, N. Mohideen, A. Hantel, and J. Pickleman Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer: Experience at a Single Institution Arch Surg, May 1, 2004; 139(5): 532 - 539. [Abstract] [Full Text] [PDF]

				S. R. DeMeester Lymph node involvement in esophageal adenocarcinoma: if you see one, have you seen them all? J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 947 - 949. [Full Text] [PDF]

				J. A. Hagen and T. R. DeMeester Staging of esophageal carcinoma J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 988 - 991. [Full Text] [PDF]

				G. M. R. Campos, S. R. DeMeester, J. H. Peters, S. Oberg, P. F. Crookes, J. A. Hagen, C. G. Bremner, L. F. Sillin III, R. J. Mason, and T. R. DeMeester Predictive Factors of Barrett Esophagus: Multivariate Analysis of 502 Patients With Gastroesophageal Reflux Disease Arch Surg, November 1, 2001; 136(11): 1267 - 1273. [Abstract] [Full Text] [PDF]

				J. A. Hagen and T. R. DeMeester Esophageal adenocarcinoma Ann. Thorac. Surg., October 1, 2001; 72(4): 1430 - 1432. [Full Text] [PDF]

				P. Flamen, A. Lerut, E. Van Cutsem, J. P. Cambier, A. Maes, W. De Wever, M. Peeters, P. De Leyn, D. Van Raemdonck, and L. Mortelmans The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J. Thorac. Cardiovasc. Surg., December 1, 2000; 120(6): 1085 - 1092. [Abstract] [Full Text] [PDF]